Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1998 1
2001 2
2003 1
2004 1
2005 1
2006 1
2007 1
2009 1
2010 1
2011 1
2012 1
2013 2
2014 3
2015 3
2016 5
2017 5
2018 10
2019 7
2020 7
2021 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Yao Z, et al. Among authors: hembrough t. Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2. Nature. 2017. PMID: 28783719 Free PMC article.
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Li BT, et al. Among authors: hembrough t. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989854 Free PMC article. Clinical Trial.
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS, Segal NH, Chaft JE, Hembrough T, Barrett JC, Hellmann MD. Zhang Q, et al. Among authors: hembrough t. Cancer Discov. 2020 Dec;10(12):1842-1853. doi: 10.1158/2159-8290.CD-20-0047. Epub 2020 Aug 14. Cancer Discov. 2020. PMID: 32816849 Free PMC article.
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.
Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, Xu D, Schumacher SE, Puschhof J, McFarland J, Zou C, Dulak A, Henderson L, Xu P, O'Day E, Rendak R, Liao WL, Cecchi F, Hembrough T, Schwartz S, Szeto C, Rustgi AK, Wong KK, Diehl JA, Jensen K, Graziano F, Ruzzo A, Fereshetian S, Mertins P, Carr SA, Beroukhim R, Nakamura K, Oki E, Watanabe M, Baba H, Imamura Y, Catenacci D, Bass AJ. Wong GS, et al. Among authors: hembrough t. Nat Med. 2018 Jul;24(7):968-977. doi: 10.1038/s41591-018-0022-x. Epub 2018 May 28. Nat Med. 2018. PMID: 29808010 Free PMC article.
Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1.
Schwarzer A, Oliveira M, Kleppa MJ, Slattery SD, Anantha A, Cooper A, Hannink M, Schambach A, Dörrie A, Kotlyarov A, Gaestel M, Hembrough T, Levine J, Luther M, Stocum M, Stiles L, Weinstock DM, Liesa M, Kostura MJ. Schwarzer A, et al. Among authors: hembrough t. Mol Cancer Ther. 2023 Nov 1;22(11):1290-1303. doi: 10.1158/1535-7163.MCT-22-0718. Mol Cancer Ther. 2023. PMID: 37643767 Free PMC article.
Overcoming hypoxia-induced functional suppression of NK cells.
Solocinski K, Padget MR, Fabian KP, Wolfson B, Cecchi F, Hembrough T, Benz SC, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW. Solocinski K, et al. Among authors: hembrough t. J Immunother Cancer. 2020 Apr;8(1):e000246. doi: 10.1136/jitc-2019-000246. J Immunother Cancer. 2020. PMID: 32345623 Free PMC article.
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Guo R, Offin M, Brannon AR, Chang J, Chow A, Delasos L, Girshman J, Wilkins O, McCarthy CG, Makhnin A, Falcon C, Scott K, Tian Y, Cecchi F, Hembrough T, Alex D, Shen R, Benayed R, Li BT, Rudin CM, Kris MG, Arcila ME, Rekhtman N, Paik P, Zehir A, Drilon A. Guo R, et al. Among authors: hembrough t. Clin Cancer Res. 2021 Feb 1;27(3):799-806. doi: 10.1158/1078-0432.CCR-20-2861. Epub 2020 Nov 10. Clin Cancer Res. 2021. PMID: 33172896 Free PMC article.
48 results